| Private Placement / Financing Transactions
Parabilis Medicines: The company raised $305 million of Series F venture funding in a deal led by RA Capital Management, Janus Henderson Investors and Fidelity Management & Research Company on January 8, 2026, putting the company’s pre-money valuation at $615 million. GV, Cormorant Asset Management, The Invus Group, Foresite Capital, Frazier Healthcare Partners, Catalio Capital Management, Sixty Degree Capital, General Catalyst, venBio, HBM Healthcare Investments, ARCH Venture Partners, Milky Way Investments Group, Nextech Invest, Samsara BioCapital, Rock Springs Capital, Farallon Capital Management, Marshall Wace, T. Rowe Price Group, Soleus Capital, Alderline Group, and other undisclosed investors also participated in the round. The company is a developer of cell-penetrating mini proteins (CPMPs) designed to target cancer-causing proteins inside cancer cells and neutralize them.
Orca Bio: The company raised $250 million of Series F venture funding through a combination of equity and debt on January 9, 2026. A series F equity portion of $150 million was led by Lightspeed Venture Partners and other undisclosed investors participated in the round. A debt financing of $100 million was provided by Silicon Valley Bank. The company is a developer of an allogeneic T-cell immunotherapy platform using purified T-cells, CD34+ stem cells, and conventional T-cells for hematologic malignancies preventing graft-versus-host disease.
AirNexis Therapeutics: The company raised $200 million of Series A venture funding in a deal led by Frazier Healthcare Partners on January 9, 2026. OrbiMed, Enavate Sciences, SR One Capital Management, Longitude Capital, Goldman Sachs Asset Management and other undiscloded investors also participated in the round. The company is a developer of novel therapeutic antibodies targeting COPD and chronic respiratory disease inflammation.
Alveus Therapeutics: The company raised $159.8 million of Series A venture funding in a deal led by Andera Partners, Omega Funds and New Rhein Healthcare on January 8, 2026, putting the company’s pre-money valuation at $123 million. Sanofi Ventures, Avego Management, Kurma Partners, and Agent Capital and other undisclosed investors also participated in the round. The company is a developer of biological and small-molecule treatments designed for metabolic disease management.
Diagonal Therapeutics: The company raised $125 million of Series B venture funding in a deal led by Sanofi Ventures and Janus Henderson Investors on January 8, 2026, putting the company’s pre-money valuation at $333.5 million. RV Invest, Frazier Healthcare Partners, Velosity Capital, Atlas Venture, Lightspeed Venture Partners, RA Capital Management, Biovision Ventures, Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management, Woodline Partners, Viking Global Investors, Checkpoint Capital, BVF Partners and other undisclosed investors also participated in the round. The company is a developer of agonist antibody therapeutics for oncology and autoimmune indications.
Kinaset Therapeutics: The company raised $103 million of Series B venture funding in a deal led by RA Capital Management and Forge Life Science Partners on January 10, 2026. Gimv, EQT Life Sciences, Vivo Capital, 5AM Ventures, Atlas Venture, Sixty Degree Capital, Schroders Capital, Willett Advisors and Pictet Alternative Advisors also participated in the round. The company is a developer of novel respiratory therapeutics targeting kinases for intractable pulmonary diseases.
Rakuten Medical: The company raised $100 million of Series F venture funding in a deal led by TaiAx Capital LP on January 7, 2026. SBI Holdings, Rakuten Group, Mitsui Sumitomo Insurance Co., Orient Europharma Company, Abies Capital, Nexuc CVC, Sumitomo Mitsui Banking Corporation, and Daiwa Securities Group also participated in the round. The company is a developer of precision-targeted cancer therapies designed to treat solid tumors.
Nocion Therapeutics: The company raised $93 million of Series B venture funding in a deal led by Arkin Capital and Monograph Capital on January 7, 2026, putting the company’s pre-money valuation at $32 million. Morningside Private Investors, Mission BioCapital, F-Prime Capital, Canaan Partners, Mass General Brigham Ventures, Lumira Ventures, Osage University Partners, and other undisclosed investors also participated in the round. The company is a developer of a small molecule charged sodium channel designed to treat conditions arising from neurogenic inflammation.
Apella: The company raised $80 million of Series B venture funding in a deal led by HIGHLANDX on January 8, 2026. Houston Methodist, PFM Health Sciences, OpAmp Capital Management, K2 HealthVentures, Vensana Capital, Casdin Capital and Upside Partnership also participated in the round. The company is a developer of intraoperative monitoring technology generating real-time physiological signals during surgical procedures.
Corsera Health: The company raised $80 million of Series A venture funding in a deal led by Population Health Partners and Forbion on January 7, 2026, putting the company’s pre-money valuation at $106 million. Ellison Institute of Technology Oxford, The Invus Group, YK Bioventures, J.M.M. Investments, and other undisclosed investors also participated in the round. The company is a developer of a cardiovascular health platform designed to predict and prevent atherosclerotic cardiovascular disease.
Mediar Therapeutics: The company raised $75.7 million of Series B venture funding in a deal led by ICG and Amplitude Ventures on January 6, 2026, putting the company’s pre-money valuation at $154.3 million. Asahi Kasei Pharma, Longwood Fund, Alexandria Real Estate Equities, and other undisclosed investors also participated in the round. The company is a developer of first-in-class antibody therapeutics targeting myofibroblasts to halt and reverse fibrosis in idiopathic pulmonary fibrosis.
Beacon Therapeutics: The company raised $75 million of Series C venture funding in a deal led by Goldman Sachs Asset Management on January 8, 2026. Advent Life Sciences, Forbion, Oxford Science Enterprises, Retinal Degeneration Fund and Syncona also participated in the round. The company is an operator of a clinical-stage biotechnology company intended to treat patients with rare lung and eye diseases.
Fineheart: The company raised EUR 35 million of Series C venture funding from Groupe Pasteur Mutualité, IRDI Capital Investissement and Lurra Capital on January 9, 2026. Doliam, European Innovation Council, Nouvelle Aquitaine Co-Investissement, ETCHART Group, Philippe Plas, Arnaud Mascarell, Philippe Ritter, Stéphane Garrigue and other undisclosed investors also participated in the round. The company is a developer of miniaturized implantable cardiac assist devices for treating advanced heart failure.
bit.bio: The company raised $50 million of Series C venture funding in a deal led by M&G on January 9, 2026. Tencent Holdings, Milky Way Research Foundation, ARCH Venture Partners, BlueYard Capital and Puhua Capital also participated in the round. The company is a developer of a synthetic biology platform designed to provide human cells for research, drug discovery and cell therapy.
Poplar Therapeutics: The company raised $50 million of Series A venture funding in a deal led by SR One Capital Management, Vida Ventures, and Platanus on January 7, 2026. Other undisclosed investors also participated in the round. The company is a developer of immunology therapeutics for food allergies and allergic disease treatment.
Vizgen: The company raised $48 million of venture funding in a deal led by M Ventures, Northpond Ventures and ARCH Venture Partners on January 8, 2026. The company is a developer of spatial genomics technology for high-resolution biomolecule profiling in tissue samples.
Ukko: The company raised $45 million of Series C venture funding in a deal led by Israel Biotech Fund on January 8, 2026. Leaps by Bayer, Sanara Capital, Khosla Ventures, Fall Line Capital, and other undisclosed investors also participated in the round. The company is a developer of immunity-boosting proteins designed to improve the lives of people who suffer from food allergies and gluten-related disorders.
Spiro Medical: The company raised $67 million of Series A venture funding in a deal led by Andera Partners, Omega Funds and Sherpa Healthcare Partners on January 5, 2026. Supernova Invest, Northern Light Venture Capital, Hero Enterprise, and HS Group also participated in the round. The company is a developer of respiratory and sleep-care diagnostic and therapeutic devices for clinics and home monitoring.
Enable Injections: The company raised $30 million of Series B venture funding from Sanofi on January 6, 2026, putting the company’s pre-money valuation at $900 million. The company is a developer of wearable drug delivery devices enabling subcutaneous administration of large-volume biologics.
Flywheel: The company raised $27.5 million of venture funding from undisclosed investors on December 31, 2025. The company is a developer of a cloud-based research data management platform accelerating biomedical research collaboration and analysis.
Luminate Medical: The company raised $21 million of debt and Series A venture funding in a deal led by Atlantic Bridge Capital, 8VC and ARTIS Ventures on January 7, 2026, putting the company’s pre-money valuation at $57 million. SciFounders, Faber Ventures, Metaplanet Holdings, Calm Ventures, Y Combinator, Finn Murphy, Steve Pacelli, Western Alliance and Elkstone also participated in the round. The company is a developer of novel medical devices improving cancer treatment delivery and patient outcomes.
Definity: The company raised $14.4 million of venture funding from undisclosed investors on January 6, 2026. The company is a developer of a centralized workforce management platform for healthcare scheduling and operational coordination.
Nested Knowledge: The company raised $4.2 million of venture funding from undisclosed investors on January 7, 2026. The company is a developer of meta-analytical research software creating living evidence libraries from published medical literature.
|
